Haemonetics (HAE) Misses Q2 EPS by 1c, Lowers FY EPS Guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $103.16 +0.23%
Revenue Growth %: +5.5%
Financial Fact:
Net income: 19.83M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.5%
Financial Fact:
Net income: 19.83M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q2 EPS of $0.60, $0.01 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $239.9 million versus the consensus estimate of $239.99 million.
GUIDANCE:
Haemonetics sees FY2022 EPS of $2.40-$2.65, versus the consensus of $2.76.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
- Morgan Stanley upgrades Synopsys as it turns selective on chip stocks
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
